Association of AGTR1 A1166C and CYP2C9∗3 Gene Polymorphisms with the Antihypertensive Effect of Valsartan

Table 1

Characteristics of hypertensive patients.

Variables	Well-controlled (n = 144)	Poorly controlled (n = 137)
Age (years)	55 (48, 62)	54 (44, 60)	0.012
Gender (male, %)	99, 68.8	104, 75.9	0.180
BMI (kg/m^2)	26.5 (24.5, 29.6)	27.2 (25.2, 29.4)	0.276
History of smoking (n, %)	51, 35.4	63, 46.0	0.071
History of drinking (n, %)	53, 36.8	67, 48.9	0.040
Grade of hypertension (n, %)			0.001
Grade 1	22, 15.3	14, 10.2
Grade 2	53, 36.8	28, 20.4
Grade 3	69, 47.9	95, 69.3
ALT (U/L)	24.0 (17.5, 34.5)	28.0 (19.0, 43.0)	0.032
TC (mmol/L)	4.3 (3.5, 5.0)	4.4 (3.6, 5.2)	0.286
TG (mmol/L)	1.6 (1.1, 2.2)	1.6 (1.2, 2.4)	0.279
LDL-C (mmol/L)	2.7 (2.1, 3.4)	2.9 (2.2, 3.6)	0.250
HDL-C (mmol/L)	1.0 (0.9, 1.2)	1.0 (0.8, 1.1)	0.045
Crea (μmol/L)	69.9 (59.1, 82.0)	70.6 (62.7, 83.4)	0.383
eGFR (ml/min per 1.73 m^2)	98.5 (89.4, 104.9)	101.5 (92.0, 107.0)	0.103

ALT: alanine aminotransferase; BMI: body mass index; Crea: creatinine; eGFR: estimated glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride. Data are shown as median (interquartile range) or %.  < 0.05 indicates statistical significance.